硫克司特 | 78299-53-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 硫克司特
• 中文别名: 硫立那特
• 英文名称: trans-3-[6-(methylthio)-4-oxo-4H-quinazolin-3-yl]-2-propenoic acid
• 英文别名: tiacrilast；(E)-3-(6-methylsulfanyl-4-oxoquinazolin-3-yl)prop-2-enoic acid
• CAS: 78299-53-3
• 化学式: C₁₂H₁₀N₂O₃S
• 分子量: 262.289
• InChiKey: VHFPVEGFRVEDBK-SNAWJCMRSA-N

物化性质

• 熔点：
  272-274 °C
• 沸点：
  499.3±55.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  95.3
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  ——	trans-3-[6-(methylthio)-4-oxo-4H-quinazolin-3-yl]-2-propenoic acid methyl ester	78299-52-2	C13H12N2O3S	276.316
  ——	6-(methylthio)quinazolin-4(3H)-one	78299-51-1	C9H8N2OS	192.241

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	(Z)-3-[6-(methylthio)-4-oxo-4H-quinazolin-3-yl]-2-propenoic acid	84118-01-4	C12H10N2O3S	262.289
  ——	trans-3-[6-(methylsulfinyl)-4-oxo-4H-quinazolin-3-yl]-2-propenoic acid	78299-68-0	C12H10N2O4S	278.288
  ——	trans-3-[6-(methylsulfonyl)-4-oxo-4H-quinazolin-3-yl]-2-propenoic acid	78312-84-2	C12H10N2O5S	294.288
  ——	6-(methylthio)-4-oxo-4H-quinazoline-3-propanoic acid	84118-02-5	C12H12N2O3S	264.305

反应信息

• 作为反应物：
  描述：

  硫克司特 以 N,N-二甲基甲酰胺 为溶剂， 反应 40.0h， 以0.22 g的产率得到(Z)-3-[6-(methylthio)-4-oxo-4H-quinazolin-3-yl]-2-propenoic acid
  参考文献：
  名称：

  (E)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acids, a new series of antiallergy agents

  摘要：

  A series of substituted (E)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acids was prepared and evaluated in the rat passive cutaneous anaphylaxis (PCA) test for antiallergic activity. Alkoxy, alkylthio, and isopropyl substituents at the 6- or 8-positions provided highly potent compounds. Conversion to the Z isomer, reduction of the side chain double bond, or reduction of the quinazoline ring resulted in substantial loss of activity. Among the analogues that exhibited oral activity in the PCA test, (E)-3-[6-(methylthio)-4-oxo-4H-quinazolin-3-yl]-2-propenoic acid (5i) was the most potent.

  DOI：

  10.1021/jm00357a018
• 作为产物：
  描述：

  5-氯-2-硝基苯甲酸 在 盐酸 、 sodium sulfide 、 sodium hydroxide 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 26.0h， 生成 硫克司特
  参考文献：
  名称：

  (E)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acids, a new series of antiallergy agents

  摘要：

  A series of substituted (E)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acids was prepared and evaluated in the rat passive cutaneous anaphylaxis (PCA) test for antiallergic activity. Alkoxy, alkylthio, and isopropyl substituents at the 6- or 8-positions provided highly potent compounds. Conversion to the Z isomer, reduction of the side chain double bond, or reduction of the quinazoline ring resulted in substantial loss of activity. Among the analogues that exhibited oral activity in the PCA test, (E)-3-[6-(methylthio)-4-oxo-4H-quinazolin-3-yl]-2-propenoic acid (5i) was the most potent.

  DOI：

  10.1021/jm00357a018

文献信息

• [EN] NOVEL BIS-CHROMONE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USES THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS DE BIS-CHROMONE, LEURS PROCÉDÉS DE PRÉPARATION ET UTILISATIONS
  申请人：UNIV GRONINGEN

  公开号：WO2014098597A1

  公开（公告）日：2014-06-26

  The invention relates to novel bis-chromone derivatives, methods for their preparation and their therapeutic application, especially in the treatment or prevention of disease involving mast cell activation, such as allergic disease. Provided is a compound according to the general Formula (I).

  这项发明涉及新型双咖啡因衍生物，其制备方法及其治疗应用，特别是在涉及肥大细胞活化的疾病的治疗或预防中，如过敏性疾病。提供的是符合一般式（I）的化合物。
• Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US04281127A1

  公开（公告）日：1981-07-28

  Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives of the formula ##STR1## wherein R.sub.1 is hydrogen, lower alkyl, lower cycloalkyl, lower alkoxy, hydroxy, halo, lower alkykthio, lower alkylsulfinyl, lower alkylsulfonyl, di-(C.sub.1 -C.sub.7)alkyl-N(CH.sub.2).sub.n O-- or 2-hydroxyethoxy; R.sub.2 is hydrogen, lower alkyl or lower alkoxy; R.sub.3 is hydroxy, lower alkoxy, di-(C.sub.1 -C.sub.7)alkyl-N(CH.sub.2).sub.n O-- or di-(C.sub.1 -C.sub.7)alkyl-N(CH.sub.2).sub.n NH--; and n is 2 to 7; provided that at least one of R.sub.1 and R.sub.2 is other than hydrogen, when R.sub.3 is hydroxy, a salt thereof with a pharmaceutically acceptable base, or when R.sub.3 is di-(C.sub.1 -C.sub.7)alkyl-N(CH.sub.2).sub.n O-- or di-(C.sub.1 -C.sub.7)alkyl-N(CH.sub.2).sub.n NH--, a salt thereof with a pharmaceutically acceptable acid, and a process for the preparation thereof, are described. The compounds of formula I are useful as agents in the prevention of allergic reactions.

  公式为##STR1##的Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid衍生物，其中R.sub.1为氢、较低烷基、较低环烷基、较低烷氧基、羟基、卤素、较低烷硫基、较低烷基磺基、较低烷基砜基、二-(C.sub.1 -C.sub.7)烷基-N(CH.sub.2).sub.n O--或2-羟基乙氧基；R.sub.2为氢、较低烷基或较低烷氧基；R.sub.3为羟基、较低烷氧基、二-(C.sub.1 -C.sub.7)烷基-N(CH.sub.2).sub.n O--或二-(C.sub.1 -C.sub.7)烷基-N(CH.sub.2).sub.n NH--；n为2至7；要求至少R.sub.1和R.sub.2中的一个不是氢，当R.sub.3为羟基时，其与药用可接受的碱的盐，或当R.sub.3为二-(C.sub.1 -C.sub.7)烷基-N(CH.sub.2).sub.n O--或二-(C.sub.1 -C.sub.7)烷基-N(CH.sub.2).sub.n NH--时，其与药用可接受的酸的盐，以及其制备方法。公式I的化合物可用作预防过敏反应的药物。
• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
  申请人：UNIV ALABAMA

  公开号：WO2010078300A1

  公开（公告）日：2010-07-08

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.

  本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物，以及其使用方法。进一步揭示了包括液态离子对的物质组合物，单独或溶解后使用；以及离子液体的“溶剂化”组合物，例如“水合”的组合物及其用途。